Prairie Capital Recapitalizes Kashi Clinical Laboratories

Prairie Capital VI Recapitalizes Legacy Hospice Holdings

January 1, 2020

Healthcare Services

Prairie Capital VI, LP partnered with CEO Clark Blair to recapitalize Legacy Hospice Holdings, Inc., a Livingston, Alabama–headquartered provider of rural hospice services. The recapitalization will support Legacy's growth initiatives, including investments in people, technology, sales & marketing, de novo site expansion and potential add-on acquisitions across its 21-office footprint serving 600+ patients daily in the Southeast.

Align Capital Partners Recapitalizes Premier Biotech

December 7, 2022

Medical Devices

Align Capital Partners has completed a recapitalization of Premier Biotech, a Minneapolis-based provider of point-of-care drugs of abuse testing devices and accredited laboratory services. Cascadia Capital served as exclusive financial advisor; Align will partner with management to scale the business, accelerate product development and expand the company's reach across workplace, government and clinical end markets.

Prairie Capital VI Recapitalizes Netalytics

February 21, 2020

Cloud & SaaS

On February 21, 2020 Prairie Capital VI, LP partnered with founders Mark and Karen Essex to recapitalize Netalytics, a Greer, South Carolina provider of electronic medical records (EMR) and practice management solutions serving the substance use disorder (SUD) / opioid use disorder (OUD) market. Prairie Capital said it will support growth through investments in human capital, sales and marketing, technology and infrastructure, service-line expansion and add-on acquisitions.

Flourish Research (NMS Capital) Recapitalizes Keystone Clinical Studies

October 6, 2022

Healthcare Services

Flourish Research, a portfolio company of NMS Capital, partnered with Keystone Clinical Studies' management in a recapitalization transaction. Keystone, a Plymouth Meeting, Pennsylvania-based clinical research site focused on Alzheimer’s disease and CNS conditions, will continue to be led by founder Dr. Cherian Verghese as part of the Flourish platform to expand CNS capabilities and enter the Philadelphia market.

Praesidian Capital Acquires Undisclosed Genetics Business

September 18, 2019

Healthcare Services

Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.

NMS-backed Flourish Research Recapitalizes Great Lakes Clinical Trials and Clinical Site Partners

January 12, 2022

Healthcare Services

NMS Capital portfolio company Flourish Research completed recapitalizations of Great Lakes Clinical Trials and Clinical Site Partners, expanding its multi-site clinical trial network across Illinois, Florida and Texas. The deals (terms undisclosed) add site capacity and management teams to Flourish Research as the platform pursues network consolidation, improved operational efficiencies and accelerated growth.